DOCSLIB.ORG

Xtrackers** Société D’Investissement À Capital Variable R.C.S

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Xtrackers** Société d’investissement à capital variable R.C.S. Luxembourg N° B-119.899 Unaudited Semi-Annual Report For the period from 1 January 2021 to 30 June 2021 No subscription can be accepted on the basis of the financial reports. Subscriptions are only valid if they are made on the basis of the latest published prospectus of Xtrackers** accompanied by the latest annual report and the most recent semi-annual report, if published thereafter. ** This includes synthetic ETFs. Xtrackers** Table of contents Page Organisation 4 Information for Hong Kong Residents 6 Statistics 7 Statement of Net Assets as at 30 June 2021 28 Statement of Investments as at 30 June 2021 48 Xtrackers MSCI WORLD SWAP UCITS ETF* 48 Xtrackers MSCI EUROPE UCITS ETF 53 Xtrackers MSCI JAPAN UCITS ETF 64 Xtrackers MSCI USA SWAP UCITS ETF* 70 Xtrackers EURO STOXX 50 UCITS ETF 74 Xtrackers DAX UCITS ETF 76 Xtrackers FTSE MIB UCITS ETF 77 Xtrackers SWITZERLAND UCITS ETF 79 Xtrackers FTSE 100 INCOME UCITS ETF 80 Xtrackers FTSE 250 UCITS ETF 83 Xtrackers MSCI UK ESG UCITS ETF 90 Xtrackers MSCI EMERGING MARKETS SWAP UCITS ETF* 94 Xtrackers MSCI EM ASIA SWAP UCITS ETF* 99 Xtrackers MSCI EM LATIN AMERICA ESG SWAP UCITS ETF*(1) 103 Xtrackers MSCI EM EUROPE, MIDDLE EAST & AFRICA ESG SWAP UCITS ETF*(2) 104 Xtrackers MSCI TAIWAN UCITS ETF 105 Xtrackers MSCI BRAZIL UCITS ETF 107 Xtrackers NIFTY 50 SWAP UCITS ETF* 109 Xtrackers MSCI KOREA UCITS ETF 111 Xtrackers FTSE CHINA 50 UCITS ETF 114 Xtrackers EURO STOXX QUALITY DIVIDEND UCITS ETF 116 Xtrackers STOXX GLOBAL SELECT DIVIDEND 100 SWAP UCITS ETF* 118 Xtrackers STOXX EUROPE 600 BASIC RESOURCES SWAP UCITS ETF* 121 Xtrackers STOXX EUROPE 600 OIL & GAS SWAP UCITS ETF* 123 Xtrackers STOXX EUROPE 600 HEALTH CARE SWAP UCITS ETF* 124 Xtrackers STOXX EUROPE 600 BANKS SWAP UCITS ETF* 126 Xtrackers STOXX EUROPE 600 TELECOMMUNICATIONS SWAP UCITS ETF* 128 Xtrackers STOXX EUROPE 600 TECHNOLOGY SWAP UCITS ETF* 129 Xtrackers STOXX EUROPE 600 UTILITIES SWAP UCITS ETF* 130 Xtrackers STOXX EUROPE 600 FOOD & BEVERAGE SWAP UCITS ETF* 132 Xtrackers STOXX EUROPE 600 INDUSTRIAL GOODS SWAP UCITS ETF* 134 Xtrackers BLOOMBERG COMMODITY EX-AGRICULTURE & LIVESTOCK SWAP UCITS ETF*(3) 135 Xtrackers SHORTDAX DAILY SWAP UCITS ETF* 137 Xtrackers EURO STOXX 50 SHORT DAILY SWAP UCITS ETF* 139 Xtrackers SLI UCITS ETF 141 Xtrackers FTSE 100 SHORT DAILY SWAP UCITS ETF* 142 Xtrackers S&P 500 INVERSE DAILY SWAP UCITS ETF* 143 Xtrackers PORTFOLIO UCITS ETF 145 Xtrackers MSCI AC ASIA EX JAPAN SWAP UCITS ETF* 146 Xtrackers MSCI PACIFIC EX JAPAN UCITS ETF 148 Xtrackers MSCI RUSSIA CAPPED SWAP UCITS ETF* 152 Xtrackers FTSE VIETNAM SWAP UCITS ETF* 154 Xtrackers LPX PRIVATE EQUITY SWAP UCITS ETF* 157 Xtrackers S&P ASX 200 UCITS ETF 159 Xtrackers STOXX EUROPE 600 UCITS ETF 164 Xtrackers S&P GLOBAL INFRASTRUCTURE SWAP UCITS ETF* 179 Xtrackers CAC 40 UCITS ETF 181 Xtrackers MSCI EUROPE MID CAP UCITS ETF 183 Xtrackers MSCI EUROPE SMALL CAP UCITS ETF 190 Xtrackers S&P SELECT FRONTIER SWAP UCITS ETF* 213 Xtrackers USD OVERNIGHT RATE SWAP UCITS ETF* 215 (1) During the period ending 30 June 2021 this Sub-Fund changed its name. Please see point 6 in the significant events of the period section of the Notes to the Financial Statements of this semi-annual report for further information. (2) During the period ending 30 June 2021 this Sub-Fund changed its name. Please see point 5 in the significant events of the period section of the Notes to the Financial Statements of this semi-annual report for further information. (3) During the period ending 30 June 2021 this Sub-Fund changed its name. Please see point 3 in the significant events of the period section of the Notes to the Financial Statements of this semi-annual report for further information. *This is a synthetic ETF. **This includes synthetic ETFs. 2 Xtrackers** Table of contents (continued) Page Xtrackers S&P 500 2X LEVERAGED DAILY SWAP UCITS ETF* 216 Xtrackers SHORTDAX X2 DAILY SWAP UCITS ETF* 218 Xtrackers LEVDAX DAILY SWAP UCITS ETF* 219 Xtrackers BLOOMBERG COMMODITY SWAP UCITS ETF*(3) 220 Xtrackers S&P 500 2X INVERSE DAILY SWAP UCITS ETF* 221 Xtrackers CSI300 SWAP UCITS ETF* 224 Xtrackers MSCI CANADA UCITS ETF 229 Xtrackers MSCI INDONESIA SWAP UCITS ETF* 232 Xtrackers MSCI MEXICO UCITS ETF 235 Xtrackers MSCI EUROPE VALUE UCITS ETF 236 Xtrackers S&P 500 SWAP UCITS ETF* 241 Xtrackers FTSE DEVELOPED EUROPE REAL ESTATE UCITS ETF 253 Xtrackers MSCI CHINA UCITS ETF 257 Xtrackers MSCI INDIA SWAP UCITS ETF* 274 Xtrackers MSCI MALAYSIA UCITS ETF 277 Xtrackers MSCI THAILAND UCITS ETF 278 Xtrackers MSCI PHILIPPINES UCITS ETF 280 Xtrackers MSCI AFRICA TOP 50 SWAP UCITS ETF* 281 Xtrackers SPAIN UCITS ETF 283 Xtrackers MSCI PAKISTAN SWAP UCITS ETF* 285 Xtrackers MSCI SINGAPORE UCITS ETF 286 Xtrackers ATX UCITS ETF 289 Xtrackers MSCI EMU UCITS ETF 290 Xtrackers DAX INCOME UCITS ETF 296 Xtrackers FTSE 100 UCITS ETF 297 Xtrackers NIKKEI 225 UCITS ETF 300 Xtrackers HARVEST CSI300 UCITS ETF 305 Xtrackers HARVEST FTSE CHINA A-H 50 UCITS ETF 318 Notes to the Financial Statements 320 Information for Shareholders 373 (3) During the period ending 30 June 2021 this Sub-Fund changed its name. Please see point 3 in the significant events of the period section of the Notes to the Financial Statements of this semi-annual report for further information. *This is a synthetic ETF. **This includes synthetic ETFs. 3 Xtrackers** Organisation Registered Office Xtrackers** 49, avenue J.F. Kennedy L-1855 Luxembourg Grand Duchy of Luxembourg Board of Directors - Thilo Wendenburg Independent director, c/o DWS Investment S.A., 2, boulevard Konrad Adenauer, L-1115 Luxembourg, Grand Duchy of Luxembourg. - Philippe Ah-Sun Global Head of Passive Operations at DWS Investments UK Limited, Winchester House, 1 Great Winchester Street, London EC2N 2DB, United Kingdom. - Alex McKenna Head of Hybrid and Liquid Solutions at DWS Investments UK Limited, Winchester House, 1 Great Winchester St, London EC2N 2DB, United Kingdom. - Freddy Brausch Member of the Luxembourg Bar, independent director, 35, avenue J. F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg. - Julien Boulliat(1) Head of Portfolio Engineering Systematic Investment Solutions at DWS Investments UK Limited, Winchester House, 1 Great Winchester St, London EC2N 2DB, United Kingdom. Depositary State Street Bank International GmbH, Luxembourg Branch 49, avenue J.F. Kennedy L-1855 Luxembourg Grand Duchy of Luxembourg Management Company DWS Investment S.A. 2, boulevard Konrad Adenauer L-1115 Luxembourg Grand Duchy of Luxembourg Administrative Agent, Paying Agent, Domiciliary Agent and Listing Agent State Street Bank International GmbH, Luxembourg Branch 49, avenue J.F. Kennedy L-1855 Luxembourg Grand Duchy of Luxembourg Registrar and Transfer Agent State Street Bank International GmbH, Luxembourg Branch 49, avenue J.F. Kennedy L-1855 Luxembourg Grand Duchy of Luxembourg (1)Julien Boulliat was appointed to the Board of Directors as at the annual general meeting held on 23 April 2021. ** This includes synthetic ETFs. 4 Xtrackers** Organisation (continued) Investment Managers / Sub-Portfolio Managers to certain Sub-Funds (see note 12) DWS Investments UK Limited Winchester House 1 Great Winchester Street London EC2N 2DB United Kingdom DWS Investment GmbH Mainzer Landstrasse 11-17 60329 Frankfurt am Main Germany DWS Investments Hong Kong Limited 60/F, International Commerce Centre 1 Austin Road West, Kowloon Hong Kong Harvest Global Investments Limited 31/F, One Exchange Square 8, Connaught Place, Central Hong Kong Securities Lending Agent to certain Sub-Funds (see note 8) Deutsche Bank AG, Frankfurt am Main head office Taunusanlage 12 60325 Frankfurt am Main Germany Deutsche Bank AG, London branch Winchester House 1 Great Winchester Street London EC2N 2DB United Kingdom Deutsche Bank AG, New York branch 60 Wall Street New York NY 10005 United States of America AuditoroftheCompany KPMG Luxembourg, Société Coopérative 39, Avenue John F. Kennedy L-1855 Luxembourg Luxembourg(2) Legal Advisers to the Company Elvinger Hoss Prussen société anonyme 2, place Winston Churchill L-1340 Luxembourg Grand Duchy of Luxembourg Hong Kong Representative DWS Investments Hong Kong Limited 60/F, International Commerce Centre 1 Austin Road West, Kowloon Hong Kong Capitalised terms used herein shall have the same meaning as in the prospectus of Xtrackers** applicable as at 30 June 2021 (the ؆Prospectus؆) unless the context requires otherwise. (2)KPMG Luxembourg Société Coopérative was appointed Auditor of the Company at the annual general meeting held on 23 April 2021. ** This includes synthetic ETFs. 5 Xtrackers** Information for Hong Kong Residents KPMG Luxembourg Société Coopérative, the Company’s auditor, is a Recognised Public Interest Entity Auditor. Sub-Funds authorised in Hong Kong As at 30 June 2021, only the following Sub-Funds of Xtrackers** (collectively the “Authorised Sub-Funds”) are authorised by the Securities and Futures Commission in Hong Kong (the “SFC”): Share Class available for Hong Sub-Fund Kong investors Xtrackers MSCI WORLD SWAP UCITS ETF* 2C Xtrackers MSCI USA SWAP UCITS ETF* 1C Xtrackers MSCI TAIWAN UCITS ETF 1C Xtrackers MSCI BRAZIL UCITS ETF 2C Xtrackers NIFTY 50 SWAP UCITS ETF* 1C Xtrackers MSCI KOREA UCITS ETF 1C Xtrackers FTSE CHINA 50 UCITS ETF 1C Xtrackers MSCI PACIFIC EX JAPAN UCITS ETF 2C Xtrackers MSCI RUSSIA CAPPED SWAP UCITS ETF* 2D Xtrackers FTSE VIETNAM SWAP UCITS ETF* 1C Xtrackers CSI300 SWAP UCITS ETF* 2D Xtrackers MSCI INDONESIA SWAP UCITS ETF* 2C Xtrackers MSCI CHINA UCITS ETF 2C Xtrackers MSCI MALAYSIA UCITS ETF 2C Xtrackers MSCI THAILAND UCITS ETF 2C Xtrackers MSCI PHILIPPINES UCITS ETF 2C Xtrackers MSCI SINGAPORE UCITS ETF 2C None of the Sub-Funds of Xtrackers**, other than the Authorised Sub-Funds, are authorised for public sale in Hong Kong nor are they available to Hong Kong residents.
Recommended publications
  • Important Notice the Depository Trust Company

    Important Notice the Depository Trust Company

    Important Notice The Depository Trust Company B #: 12945-20 Date: February 10, 2020 To: All Participants Category: Dividends | International From: Global Tax Services Attention: Managing Partner/Officer, Cashier, Dividend Mgr., Tax Mgr. BNY Mellon | ADRs | Qualified Dividends for Tax Year 2019 Subject: Bank of New York Mellon Corporation (“BNYM”), as depositary for these issues listed below has reviewed and determined if they met the criteria for reduced U.S. tax rate as “qualified dividends” for tax year 2019. The Depository Trust Company received the attached correspondence containing Tax Information. If applicable, please consult your tax advisor to ensure proper treatment of these events. Non-Confidential DTCC Public (White) 2019 DIVIDEND CERTIFICATION CUSIP DR Name Country Exchange Qualified 000304105 AAC TECHNOLOGIES HLDGS INC CAYMAN ISLANDS OTC N 000380105 ABCAM PLC UNITED KINGDOM OTC Y 001201102 AGL ENERGY LTD AUSTRALIA OTC Y 001317205 AIA GROUP LTD HONG KONG OTC N 002482107 A2A SPA ITALY OTC Y 003381100 ABERTIS INFRAESTRUCTURAS S A SPAIN OTC Y 003725306 ABOITIZ EQUITY VENTURES INC PHILIPPINES OTC Y 003730108 ABOITIZ PWR CORP PHILIPPINES OTC Y 004563102 ACKERMANS & VAN HAAREN BELGIUM OTC Y 004845202 ACOM CO. JAPAN OTC Y 006754204 ADECCO GROUP AG SWITZERLAND OTC Y 007192107 ADMIRAL GROUP UNITED KINGDOM OTC Y 007627102 AEON CO LTD JAPAN OTC Y 008712200 AIDA ENGR LTD JAPAN OTC Y 009126202 AIR LIQUIDE FRANCE OTC Y 009279100 AIRBUS SE NETHERLANDS OTC Y 009707100 AJINOMOTO INC JAPAN OTC Y 015096209 ALEXANDRIA MINERAL - REG. S EGYPT None N 015393101 ALFA LAVAL AB SWEDEN SWEDEN OTC Y 021090204 ALPS ELEC LTD JAPAN OTC Y 021244207 ALSTOM FRANCE OTC Y 022205108 ALUMINA LTD AUSTRALIA OTC Y 022631204 AMADA HLDGS CO LTD JAPAN OTC Y 023511207 AMER GROUP HOLDING - REG.
  • Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm

    Kopi Af Aktivlisten 2021-06-30 Ny.Xlsm

    Velliv noterede aktier i alt pr. 30-06-2021 ISIN Udstedelsesland Navn Markedsværdi (i DKK) US0378331005 US APPLE INC 1.677.392.695 US5949181045 US MICROSOFT CORP 1.463.792.732 US0231351067 US AMAZON.COM INC 1.383.643.996 DK0060534915 DK NOVO NORDISK A/S-B 1.195.448.146 US30303M1027 US FACEBOOK INC-CLASS A 1.169.094.867 US02079K3059 US ALPHABET INC-CL A 867.740.769 DK0010274414 DK DANSKE BANK A/S 761.684.457 DK0060079531 DK DSV PANALPINA A/S 629.313.827 US02079K1079 US ALPHABET INC-CL C 589.305.120 US90138F1021 US TWILIO INC - A 514.807.852 US57636Q1040 US MASTERCARD INC - A 490.766.560 US4781601046 US JOHNSON & JOHNSON 478.682.981 US70450Y1038 US PAYPAL HOLDINGS INC 471.592.728 DK0061539921 DK VESTAS WIND SYSTEMS A/S 441.187.698 US79466L3024 US SALESFORCE.COM INC 439.114.061 US01609W1027 US ALIBABA GROUP HOLDING-SP ADR 432.325.255 US8835561023 US THERMO FISHER SCIENTIFIC INC 430.036.612 US22788C1053 US CROWDSTRIKE HOLDINGS INC - A 400.408.622 KYG875721634 HK TENCENT HOLDINGS LTD 397.054.685 KR7005930003 KR SAMSUNG ELECTRONICS CO LTD 389.413.700 DK0060094928 DK ORSTED A/S 378.578.374 ES0109067019 ES AMADEUS IT GROUP SA 375.824.429 US46625H1005 US JPMORGAN CHASE & CO 375.282.618 US67066G1040 US NVIDIA CORP 357.034.119 US17275R1023 US CISCO SYSTEMS INC 348.160.692 DK0010244508 DK AP MOLLER-MAERSK A/S-B 339.783.859 US20030N1019 US COMCAST CORP-CLASS A 337.806.502 NL0010273215 NL ASML HOLDING NV 334.040.559 CH0012032048 CH ROCHE HOLDING AG-GENUSSCHEIN 325.008.200 KYG970081173 HK WUXI BIOLOGICS CAYMAN INC 321.300.236 US4370761029 US HOME DEPOT INC 317.083.124 US58933Y1055 US MERCK & CO.
  • Jefferies 2013 Global Healthcare Conference in London

    Jefferies 2013 Global Healthcare Conference in London

    Jefferies 2013 Global Healthcare Conference in London At the 2012 Jefferies Global Healthcare Conference, there were well over 200 healthcare companies participating with a combined market cap of $1 trillion and close to 1,300 one-on-one/small group meetings over the two-day event. The 2013 conference is set to follow the same footsteps, featuring public and private leading INVITATION global healthcare companies within the areas of pharmaceuticals, biotech, generics, 20-21 NOVEMBER 2013 medtech and healthcare services from the US, Central and Eastern Europe, Latin The Waldorf Hilton America, India, China, Japan, Egypt, Israel and Russia. London, UK Throughout the two-day event, we will feature concurrent tracks of informative presentations as well as 1x1/small group meetings, and thematic panel discussions. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare. We hope you can join us for what promises to be a unique and comprehensive view of the industry. Registration is now open. Please email your Jefferies representative if you are interested in attending. For general questions, please email [email protected] or contact your Jefferies representative. © 2013 Jefferies LLC. Member SIPC. AGENDA WEDNESDAY, 20 NOVEMBER 2013 Jefferies 2013 Global Healthcare Conference in London ADELPHI 1 ADELPHI 2 ADELPHI 3 EXECUTIVE BOARDROOM 7:30 AM Breakfast & Registration 8:00 AM Clinigen Group Plc Ion Beam Applications Active Biotech AB Syneron Medical Ltd. Specialty Pharma & Healthcare Services Medical Products Biotechnology Medical Technology Paul Thomas; CTO Olivier Legrain, CEO Tomas Leanderson; President and CEO Hugo Goldman, CFO 8:40 AM Valneva Celltrion, Inc.
  • Blackrock UK Smaller Companies PDF Factsheet

    Blackrock UK Smaller Companies PDF Factsheet

    Adventurous 31 August 2021 Life Fund SW BlackRock UK Smaller Companies Life Asset Allocation (as at 31/07/2021) This document is provided for the purpose of UK Small Cap Companies 99.8% information only. This factsheet is intended for individuals who are familiar with investment Money Market 0.2% terminology. Please contact your financial adviser if you need an explanation of the terms used. This material should not be relied upon as sufficient information to support an investment decision. The portfolio data on this factsheet is updated on a quarterly basis. Fund Aim The fund aims for long-term growth by investing in UK smaller companies which the Fund Manager considers to have above average long-term growth prospects. The fund Sector Breakdown (as at 31/07/2021) invests solely through the BlackRock UK Consumer Discretionary 27.7% Smaller Companies Unit Trust. Industrials 25.1% Basic Fund Information Financials 12.2% Fund Launch Date 19/09/2001 Technology 11.3% Fund Size £5.3m Basic Materials 5.1% Sector ABI UK Smaller Other 4.9% Companies Energy 3.8% ISIN GB0030873565 Consumer Staples 3.8% MEX ID SWMUL Health Care 3.7% SEDOL 3087356 Telecommunications 2.5% Manager Name Roland Arnold Regional Breakdown (as at 31/07/2021) Manager Since 26/03/2015 Top Ten Holdings (as at 31/07/2021) WATCHES OF SWITZERLAND 2.9% GROUP PLC IMPAX ASSET MANAGEMENT 2.4% GROUP PLC TREATT PLC 2.2% The composition of asset mix and asset allocation may change at any time and exclude cash CVS GROUP PLC 2.1% unless otherwise stated BREEDON GROUP PLC 2.0% OXFORD INSTRUMENTS PLC 1.8% INTEGRAFIN HOLDINGS PLC 1.8% AUCTION TECHNOLOGY GROUP 1.7% PLC ERGOMED PLC 1.7% LEARNING TECHNOLOGIES GROUP 1.7% PL TOTAL 20.3% Page 1 Past Performance Fund Rating Information 100% Overall Morningstar **** Rating Morningstar Analyst Rating 50% FE fundinfo Crown Rating The FE fundinfo Crown Rating relates to this fund.
  • PKA's Beholdningsliste Januar 2021

    PKA's Beholdningsliste Januar 2021

    PKA's beholdningsliste januar 2021 Børsnoterede aktier MV (DKK) Andel 1&1 DRILLISCH AG 10.490.498 0,02% 10X GENOMICS INC-CLASS A 2.145.776 0,00% 1Life Healthcare Ord Shs 6.571.542 0,01% 3I GROUP PLC 17.062.491 0,03% 3M CO 302.713.200 0,50% 7-ELEVEN MALAYSIA HOLDINGS B 211.131 0,00% A.G.V. PRODUCTS 192.174 0,00% A2A SPA 17.183.182 0,03% ABB LTD-REG 32.093.403 0,05% ABBOTT LABORATORIES 87.115.671 0,14% ABBVIE INC 96.660.415 0,16% ABC-MART INC 2.062.282 0,00% ABN AMRO BANK NV-CVA 5.059.876 0,01% ABSA GROUP LTD 406.300 0,00% ABU DHABI COMMERCIAL BANK 3.584.050 0,01% ACADIA HEALTHCARE CO INC 21.882.527 0,04% ACCENTURE PLC-CL A 334.903.403 0,55% ACCOR SA 6.759.805 0,01% ACER INC 8.743.663 0,01% ACERINOX, S.A. CMN 403.993 0,00% ACI WORLDWIDE INC 6.718.889 0,01% ACOM CO LTD 1.287.818 0,00% ACS ACTIVIDADES CONS Y SERV 41.435.966 0,07% ACTIVISION BLIZZARD INC 162.312.882 0,27% ACUITY BRANDS INC 4.043.255 0,01% ADECCO GROUP AG-REG 43.725.297 0,07% ADIDAS AG 42.007.239 0,07% ADIRA DINAMIKA MULTI FINANCE 147.645 0,00% ADOBE INC 143.959.583 0,24% ADP 1.829.359 0,00% ADT INC 8.947.846 0,01% ADTALEM GLOBAL EDUCATION INC 4.652.590 0,01% ADTRAN INC 7.367.810 0,01% ADVANCE AUTO PARTS INC 3.356.655 0,01% ADVANCED INFO SERVICE-FOR RG 57.968.026 0,09% ADVANCED INFO SERVICE-NVDR 4.148.020 0,01% ADVANCED MICRO DEVICES 48.350.398 0,08% ADVANTEST CORP 16.311.717 0,03% ADYEN B.
  • Description Iresscode Exchange Current Margin New Margin 3I

    Description Iresscode Exchange Current Margin New Margin 3I

    Description IRESSCode Exchange Current Margin New Margin 3I INFRASTRUCTURE PLC 3IN LSE 20 20 888 HOLDINGS PLC 888 LSE 20 20 ASSOCIATED BRITISH ABF LSE 10 10 ADMIRAL GROUP PLC ADM LSE 10 10 AGGREKO PLC AGK LSE 20 20 ASHTEAD GROUP PLC AHT LSE 10 10 ANTOFAGASTA PLC ANTO LSE 15 10 ASOS PLC ASC LSE 20 20 ASHMORE GROUP PLC ASHM LSE 20 20 ABERFORTH SMALLER COM ASL LSE 20 20 AVEVA GROUP PLC AVV LSE 20 20 AVIVA PLC AV LSE 10 10 ASTRAZENECA PLC AZN LSE 10 10 BABCOCK INTERNATIONAL BAB LSE 20 20 BARR PLC BAG LSE 25 20 BARCLAYS PLC BARC LSE 10 10 BRITISH AMERICAN TOBA BATS LSE 10 10 BAE SYSTEMS PLC BA LSE 10 10 BALFOUR BEATTY PLC BBY LSE 20 20 BARRATT DEVELOPMENTS BDEV LSE 10 10 BARING EMERGING EUROP BEE LSE 50 100 BEAZLEY PLC BEZ LSE 20 20 BH GLOBAL LIMITED BHGG LSE 30 100 BOWLEVEN PLC BLVN LSE 60 50 BANKERS INVESTMENT BNKR LSE 20 20 BUNZL PLC BNZL LSE 10 10 BODYCOTE PLC BOY LSE 20 20 BP PLC BP LSE 10 10 BURBERRY GROUP PLC BRBY LSE 10 10 BLACKROCK WORLD MININ BRWM LSE 20 65 BT GROUP PLC BT-A LSE 10 10 BRITVIC PLC BVIC LSE 20 20 BOVIS HOMES GROUP PLC BVS LSE 20 20 BROWN GROUP PLC BWNG LSE 25 20 BELLWAY PLC BWY LSE 20 20 BIG YELLOW GROUP PLC BYG LSE 20 20 CENTRAL ASIA METALS PLC CAML LSE 40 30 CLOSE BROTHERS GROUP CBG LSE 20 20 CARNIVAL PLC CCL LSE 10 10 CENTAMIN PLC CEY LSE 20 20 CHARIOT OIL & GAS LTD CHAR LSE 100 100 CHEMRING GROUP PLC CHG LSE 25 20 CONYGAR INVESTMENT CIC LSE 50 40 CALEDONIA INVESTMENTS CLDN LSE 25 20 CARILLION PLC CLLN LSE 100 100 COMMUNISIS PLC CMS LSE 50 100 CENTRICA PLC CNA LSE 10 10 CAIRN ENERGY PLC CNE LSE 30 30 COBHAM PLC
  • The VT Redlands Portfolios

    The VT Redlands Portfolios

    The VT Redlands Portfolios What are the VT Redlands Portfolios? The VT Redlands Portfolio funds each invest in one of four defined “asset classes” namely the Equity, Multi-Asset, Property and Fixed Income categories. Each fund carries a prescribed Risk Profile on a scale of 1 to 7 – with for example Equity being the highest at a factor 5. Each one is used as a building block in the creation of bespoke risk rated investment portfolios for clients of David Williams IFA. By combining the four VT Redlands funds with other asset classes such as With Profits/ Smoothed Managed and Structured Equity funds, our clients can enjoy the benefits of a very wide level of diversification within their portfolios. This reduces volatility and creates the potential for rewarding rates of return year after year. Each Portfolio fund is constructed as a Fund of Funds providing access to the “best of the best” sector funds from a huge investment universe. The Portfolios are designed to meet their objectives as efficiently as possible whilst keeping costs to a minimum and are run according to a strict risk-control criteria. Typically, 15 to 25 different funds are held in each portfolio, with each one in turn managed by leading investment houses such as Fundsmith, Fidelity and Invesco as well as specialist boutiques including Ruffer, Fulcrum and Somerset. Underlying funds have exposure to a great many shares, bonds and other assets, Therefore, a single investment into one of the Redlands Portfolios gives a spread across a myriad of different holdings, countries and investment styles.
  • Parker Review

    Parker Review

    Ethnic Diversity Enriching Business Leadership An update report from The Parker Review Sir John Parker The Parker Review Committee 5 February 2020 Principal Sponsor Members of the Steering Committee Chair: Sir John Parker GBE, FREng Co-Chair: David Tyler Contents Members: Dr Doyin Atewologun Sanjay Bhandari Helen Mahy CBE Foreword by Sir John Parker 2 Sir Kenneth Olisa OBE Foreword by the Secretary of State 6 Trevor Phillips OBE Message from EY 8 Tom Shropshire Vision and Mission Statement 10 Yvonne Thompson CBE Professor Susan Vinnicombe CBE Current Profile of FTSE 350 Boards 14 Matthew Percival FRC/Cranfield Research on Ethnic Diversity Reporting 36 Arun Batra OBE Parker Review Recommendations 58 Bilal Raja Kirstie Wright Company Success Stories 62 Closing Word from Sir Jon Thompson 65 Observers Biographies 66 Sanu de Lima, Itiola Durojaiye, Katie Leinweber Appendix — The Directors’ Resource Toolkit 72 Department for Business, Energy & Industrial Strategy Thanks to our contributors during the year and to this report Oliver Cover Alex Diggins Neil Golborne Orla Pettigrew Sonam Patel Zaheer Ahmad MBE Rachel Sadka Simon Feeke Key advisors and contributors to this report: Simon Manterfield Dr Manjari Prashar Dr Fatima Tresh Latika Shah ® At the heart of our success lies the performance 2. Recognising the changes and growing talent of our many great companies, many of them listed pool of ethnically diverse candidates in our in the FTSE 100 and FTSE 250. There is no doubt home and overseas markets which will influence that one reason we have been able to punch recruitment patterns for years to come above our weight as a medium-sized country is the talent and inventiveness of our business leaders Whilst we have made great strides in bringing and our skilled people.
  • The Virgin UK Index Tracking Trust

    The Virgin UK Index Tracking Trust

    The Virgin UK Index Tracking Trust Final Report and Financial Statements For the year ended 15 March 2021 2 The Virgin UK Index Tracking Trust Contents Manager's report 3 Management and professional services 3 Manager's investment report 4 Comparative tables 11 Portfolio statement 12 Top purchases and sales of investments 30 Securities Financing Transactions (SFTs) 32 Statement of total return 36 Statement of change in net assets attributable to unitholders 37 Balance sheet 38 Notes to the financial statements 39 Distribution tables 53 Statement of the Manager’s responsibilities 54 Independent auditor’s report to the unitholders of the Virgin UK Index Tracking Trust 55 Manager’s remuneration 58 Statement of the Trustee’s responsibilities in respect of the Scheme and Report of the Trustee to the Unitholders of the Virgin UK Index Tracking Trust 59 The Virgin UK Index Tracking Trust 3 Management and professional services For the year ended 15 March 2021 Manager (the ‘Manager’) Virgin Money Unit Trust Managers Limited Jubilee House Directors: S. Bruce (appointed 29 September 2020) Gosforth J. Byrne (appointed 24 May 2021) Newcastle upon Tyne H. Chater NE3 4PL S. Fennessy (resigned 29 September 2020) F. Murphy (appointed 19 October 2020) M. Phibbs J. Scott (resigned 4 December 2020) I. Smith (resigned 19 October 2020) D. Taylor (appointed 29 September 2020) N. L. Tu (resigned 24 May 2021) S. Wemyss (appointed 8 December 2020) Telephone 03456 10 20 30* Authorised and regulated by the Financial Conduct Authority. Investment adviser Aberdeen Asset Managers Limited 10 Queen’s Terrace Aberdeen Aberdeenshire AB10 1XL Authorised and regulated by the Financial Conduct Authority.
  • Life After Lockdown

    Life After Lockdown

    www.whatinvestment.co.uk Issue 460 | July 2021 | £4.50 LIFE AFTER LOCKDOWN A growing concern Are you switched on? A high stakes game Investing in trees could How artifi cial intelligence Peter Elston on why be the antidote to some of is transforming life as infl ation is far more Earth’s biggest challenges we know it complex than it appears Pages 34-35 Pages 50-52 Page 82 001_WI_0721.indd 1 17/06/2021 10:42 ad template.indd 1 17/06/2021 12:02 First word 3 July 2021 On life and investing www.whatinvestment.co.uk Issue 460 | July 2021 | £4.50 LIFE AFTER LOCKDOWN after the pandemic A growing concern Are you switched on? A high stakes game Investing in trees could How artificial intelligence Peter Elston on why be the antidote to some of is transforming life as inflation is far more Earth’s biggest challenges we know it complex than it appears Pages 34-35 Pages 50-52 Page 82 elcome to the July issue As you will learn in this month’s Editorial of What Investment, which issue, some investment trust Editor-in-chief comes at a time when it managers believe there will be a Lawrence Gosling 020 7250 7027 W [email protected] looks like the economy is on the very strong recovery, particularly verge of opening up for the fi rst in areas like consumer spending, Subscriptions Lara Rossett 020 7250 7011 time since March of last year. housebuilding and specialist [email protected] How we view this situation industrial businesses; others don’t Advertising depends largely on what kind of Lawrence Gosling think things will be so simple.
  • March 2018 1 MARKET UPDATE| HEALTHCARE

    March 2018 1 MARKET UPDATE| HEALTHCARE

    MARKET UPDATE| HEALTHCARE MARKET UPDATE HEALTHCARE March 2018 1 MARKET UPDATE| HEALTHCARE HIGHLIGHTS Dear Reader, 2017 ended with the $69 billion CVS Health / Aetna deal. Pharmacy +6.5% Benefit Manager (PBM) consolidation took another major step this month 5Y-CAGR with Cigna scooping up the largest independent PBM, Express Scripts, in a $52 billion deal. Additionally, rumor has it that Walmart is in the early Worldwide stages talks with insurer Humana, looking at a variety of options including prescription drugs - an acquisition. The frenzy might very well be due to Amazon’s debut in expected sales healthcare and the looming shadow of its entrance in the pharmacy market. But Amazon is also putting pressure on consumer care products, intensifying price competition. In response, pharmaceuticals groups are +5.3% parted between those which want to hold on to these products that are 5Y-CAGR generally durable brands with loyal customers, and others which doubt Medtech market - their long-term stable returns. GlaxoSmithKline had us hold our breath: expected growth after entering - and eventually quitting - the race to buy Pfizer’s consumer healthcare business for a price tag hoped to be as much as $20 billion, the company bought Novartis out of their consumer healthcare joint venture for $13 billion. GSK is thus taking full control of products -0.7%/-2.2% including Sensodyne toothpaste, Panadol headache tablets and muscle gel Monthly EU Pharma & Voltaren. biotech performance March was also home to remarkable market transactions in the biotech and medtech fields that had us quite excited, beyond the fact that Bryan, Garnier & Co.
  • Opioid Dependence: Buprenorphine Prolonged- Release Injection (Buvidal)

    Opioid Dependence: Buprenorphine Prolonged- Release Injection (Buvidal)

    Evidence review Opioid dependence: buprenorphine prolonged- release injection (Buvidal) Publication date: February 2019 This evidence review sets out the best available evidence on buprenorphine prolonged-release injection (Buvidal) for treating opioid dependence. It should be read in conjunction with the evidence summary, which gives the key messages. Commissioned by Public Health England. Disclaimer The content of this evidence review was up-to-date in February 2019. See summaries of product characteristics (SPCs), British national formulary (BNF) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Copyright © NICE 2019. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3246-7 Evidence review: Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (February 2019) 2 of 29 Contents Contents ..................................................................................................................... 3 Background ................................................................................................................ 4 Product overview ........................................................................................................ 4 Mode of action ........................................................................................................ 4 Regulatory status .................................................................................................... 4 Dosing information .................................................................................................